JonesTrading analyst Soumit Roy has maintained their bullish stance on TARA stock, giving a Buy rating today.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Soumit Roy’s rating is based on Protara Therapeutics’ progress with their bladder cancer drug, TARA-002, which is moving into a pivotal study for BCG-Naive patients. The company has received alignment from the FDA to conduct this trial, which will compare TARA-002 against physician’s choice of intravesical-delivered chemotherapy.
The trial’s primary endpoint is set as complete response (CR) at six months, which is considered a straightforward measure compared to other trials. Additionally, Protara has provided benchmarks for CR rates based on historical data, which supports the potential efficacy of TARA-002. These factors, combined with the company’s financial stability, contribute to the Buy rating.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $26.00 price target.